| BID | 0.9810 | ASK | 1.01 | ||
| Open | 1.01 | Previous Close | 0.9800 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 13.00 | Analyst Rating | — 0.00 | |
| Potential % | 1.21K | Finscreener Ranking | ★★★★★ 62.44 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★+ 49.45 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★+ 54.49 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 8.68 | Earnings Rating | Neutral | |
| Market Cap | 16.65M | Earnings Date | 12th Jan 2024 | |
| Alpha | 0.01 | Standard Deviation | 0.27 | |
| Beta | -0.65 |
Today's Price Range 0.98001.02 | 52W Range 0.70404.00 | 5 Year PE Ratio Range -20.90-13.70 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 8.89% | ||
| 1 Month | 16.53% | ||
| 3 Months | -22.22% | ||
| 6 Months | -24.62% | ||
| 1 Year | -74.24% | ||
| 3 Years | -85.57% | ||
| 5 Years | -63.70% | ||
| 10 Years | 19.51% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -33.87 | |||
ROE last 12 Months | -59.10 | |||
ROA (5Y Avg) | -15.00 | |||
ROA last 12 Months | -44.85 | |||
ROC (5Y Avg) | -25.30 | |||
ROC last 12 Months | -50.71 | |||
Return on invested Capital Q | -21.43 | |||
Return on invested Capital Y | -44.25 | |||
Assets Turnover | 0.50 | |||
Receivables Turnover | 4.70 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -8.40 | ||||
| 5.44 | ||||
| 3.14 | ||||
| 16.00 | ||||
| -12.80 | ||||
| -0.17 | ||||
| 5.44 | ||||
| 0.62 | ||||
| 40.51M | ||||
| Forward PE | 23.25 | |||
| PEG | -0.37 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 4.00 | ||||
| 5.20 | ||||
| 0.10 | ||||
| 0.16 | ||||
| -31 442.60 | ||||
| Leverage Ratio | 1.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 15.70 | ||||
| -26.20 | ||||
| -23.10 | ||||
| -82.70 | ||||
| -26.95 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 14.60M | ||||
| 1.08 | ||||
| 40.05 | ||||
| 13.28 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2024 | - | -0.07 | - |
| Q03 2023 | - | -0.12 | - |
| Q02 2023 | - | -0.12 | - |
| Q01 2023 | - | -0.16 | - |
| Q04 2022 | - | -0.14 | - |
| Q03 2022 | -0.10 | -0.01 | 90.00 |
| Q02 2022 | -0.08 | -0.09 | -12.50 |
| Q01 2022 | -0.12 | -0.12 | 0.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 5/2021 QR | -0.03 | -200.00 | Negative |
| 2/2022 QR | -0.10 | 74.36 | Positive |
| 5/2022 FY | -0.43 | 0.00 | - |
| 5/2023 FY | 0.04 | 0.00 | - |
| Next Report Date | 12th Jan 2024 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 6.31K |
| Shares Outstanding | 16.82K |
| Shares Float | 14.55M |
| Trades Count | 59 |
| Dollar Volume | 6.28K |
| Avg. Volume | 40.69K |
| Avg. Weekly Volume | 39.63K |
| Avg. Monthly Volume | 27.70K |
| Avg. Quarterly Volume | 54.75K |
Biomerica Inc. (NASDAQ: BMRA) stock closed at 0.98 per share at the end of the most recent trading day (a 4.26% change compared to the prior day closing price) with a volume of 89.46K shares and market capitalization of 16.65M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 45 people. Biomerica Inc. CEO is Zackary S. Irani.
The one-year performance of Biomerica Inc. stock is -74.24%, while year-to-date (YTD) performance is -70.75%. BMRA stock has a five-year performance of -63.7%. Its 52-week range is between 0.704 and 4, which gives BMRA stock a 52-week price range ratio of 8.68%
Biomerica Inc. currently has a PE ratio of -8.40, a price-to-book (PB) ratio of 5.44, a price-to-sale (PS) ratio of 3.14, a price to cashflow ratio of 16.00, a PEG ratio of -0.37, a ROA of -44.85%, a ROC of -50.71% and a ROE of -59.10%. The company’s profit margin is -26.95%, its EBITDA margin is -23.10%, and its revenue ttm is $14.60 Million , which makes it $1.08 revenue per share.
Of the last four earnings reports from Biomerica Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Biomerica Inc.’s next earnings report date is 12th Jan 2024.
The consensus rating of Wall Street analysts for Biomerica Inc. is — (0), with a target price of $13, which is +1 213.13% compared to the current price. The earnings rating for Biomerica Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Biomerica Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Biomerica Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 21.52, ATR14 : 0.08, CCI20 : 226.38, Chaikin Money Flow : 0.10, MACD : 0.01, Money Flow Index : 64.65, ROC : 8.89, RSI : 59.09, STOCH (14,3) : 66.67, STOCH RSI : 1.00, UO : 60.50, Williams %R : -33.33), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Biomerica Inc. in the last 12-months were: Allen C. Barbieri (Buy at a value of $4 522), Barbieri Allen (Buy at a value of $4 522), Catherine Coste (Buy at a value of $6 482), Coste Catherine (Buy at a value of $6 482), Zachary S. Irani (Buy at a value of $10 750), Zacharys Irani (Buy at a value of $30 904)
Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. Majority of the company's revenue is earned from the Europe market.
CEO: Zackary S. Irani
Telephone: +1 949 645-2111
Address: 17571 Von Karman Avenue, Irvine 92614, CA, US
Number of employees: 45
